Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Kaiser

Showing results (91-100 of 160) with videos related to

Pageof 16
Sort By:
Blood Cancer Journal|October 15, 2020
An enhanced genetic model of relapsed IGH-translocated multiple myeloma evolutionary dynamicsPhuc H Hoang, Alex J Cornish, Amy L Sherborne, et al.
Ejhaem|June 18, 2025
Risk adapted therapy for newly diagnosed multiple myeloma delivered through local cytogenetic laboratories in a National Clinical Trial: UKMRA RADAR studyDipal Mehta, Robert Cicero, Laura Chiecchio, et al.
Angewandte Chemie (International Ed. in English)|May 3, 2021
Tricyanidoferrates(-IV) and Ruthenates(-IV) with Non-Innocent Cyanido LigandsFranziska Jach, Frank R Wagner, Zeeshan H Amber, et al.
Leukemia|October 16, 2019
The relative importance of factors predicting outcome for myeloma patients at different ages: results from 3894 patients in the Myeloma XI trialCharlotte Pawlyn, David Cairns, Martin Kaiser, et al.
BMC Hematology|May 19, 2016
The MUK five protocol: a phase II randomised, controlled, parallel group, multi-centre trial of carfilzomib, cyclophosphamide and dexamethasone (CCD) vs. cyclophosphamide, bortezomib (Velcade) and dexamethasone (CVD) for first relapse and primary refractory multiple myelomaSarah Brown, Samantha Hinsley, Mónica Ballesteros, et al.
Haematologica|December 10, 2020
Autologous stem cell transplantation is safe and effective for fit older myeloma patients: exploratory results from the Myeloma XI trialCharlotte Pawlyn, David Cairns, Tom Menzies, et al.
British Journal of Haematology|June 12, 2020
Early relapse after high-dose melphalan autologous stem cell transplant predicts inferior survival and is associated with high disease burden and genetically high-risk disease in multiple myelomaCeri Bygrave, Charlotte Pawlyn, Faith Davies, et al.
Scientific Reports|July 25, 2015
Implementation of genome-wide complex trait analysis to quantify the heritability in multiple myelomaJonathan S Mitchell, David C Johnson, Kevin Litchfield, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 1, 2021
Sex Differences in Multiple Myeloma Biology but not Clinical Outcomes: Results from 3894 Patients in the Myeloma XI TrialSarah Bird, David Cairns, Tom Menzies, et al.
Nature Communications|November 25, 2016
Multiple myeloma risk variant at 7p15.3 creates an IRF4-binding site and interferes with CDCA7L expressionNi Li, David C Johnson, Niels Weinhold, et al.
Pageof 16

Showing results (91-100 of 160) with videos related to

Sort By:
Pageof 16
Blood Cancer Journal|October 15, 2020
An enhanced genetic model of relapsed IGH-translocated multiple myeloma evolutionary dynamicsPhuc H Hoang, Alex J Cornish, Amy L Sherborne, et al.
Ejhaem|June 18, 2025
Risk adapted therapy for newly diagnosed multiple myeloma delivered through local cytogenetic laboratories in a National Clinical Trial: UKMRA RADAR studyDipal Mehta, Robert Cicero, Laura Chiecchio, et al.
Angewandte Chemie (International Ed. in English)|May 3, 2021
Tricyanidoferrates(-IV) and Ruthenates(-IV) with Non-Innocent Cyanido LigandsFranziska Jach, Frank R Wagner, Zeeshan H Amber, et al.
Leukemia|October 16, 2019
The relative importance of factors predicting outcome for myeloma patients at different ages: results from 3894 patients in the Myeloma XI trialCharlotte Pawlyn, David Cairns, Martin Kaiser, et al.
BMC Hematology|May 19, 2016
The MUK five protocol: a phase II randomised, controlled, parallel group, multi-centre trial of carfilzomib, cyclophosphamide and dexamethasone (CCD) vs. cyclophosphamide, bortezomib (Velcade) and dexamethasone (CVD) for first relapse and primary refractory multiple myelomaSarah Brown, Samantha Hinsley, Mónica Ballesteros, et al.
Haematologica|December 10, 2020
Autologous stem cell transplantation is safe and effective for fit older myeloma patients: exploratory results from the Myeloma XI trialCharlotte Pawlyn, David Cairns, Tom Menzies, et al.
British Journal of Haematology|June 12, 2020
Early relapse after high-dose melphalan autologous stem cell transplant predicts inferior survival and is associated with high disease burden and genetically high-risk disease in multiple myelomaCeri Bygrave, Charlotte Pawlyn, Faith Davies, et al.
Scientific Reports|July 25, 2015
Implementation of genome-wide complex trait analysis to quantify the heritability in multiple myelomaJonathan S Mitchell, David C Johnson, Kevin Litchfield, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 1, 2021
Sex Differences in Multiple Myeloma Biology but not Clinical Outcomes: Results from 3894 Patients in the Myeloma XI TrialSarah Bird, David Cairns, Tom Menzies, et al.
Nature Communications|November 25, 2016
Multiple myeloma risk variant at 7p15.3 creates an IRF4-binding site and interferes with CDCA7L expressionNi Li, David C Johnson, Niels Weinhold, et al.
Pageof 16